Why is Glaxosmi. Pharma falling/rising?

As of 27-Jun, Glaxosmithkline Pharmaceuticals Ltd is experiencing a price increase, currently at 3,457.70, which reflects a rise of 180.05 or 5.49%. The stock has shown strong performance recently, gaining 8.92% over the last four days and is now just 1.68% away from its 52-week high. It has outperformed its sector by 4.61% today and is trading above all its key moving averages. The company also boasts a high return on equity of 42.32% and a low debt-to-equity ratio, which contributes positively to investor sentiment. However, there are concerns regarding its long-term growth, as net sales have only grown at an annual rate of 3.06% over the past five years, indicating potential risks despite the recent positive performance.
Broader market context shows that Glaxosmithkline Pharmaceuticals Ltd has significantly outperformed the benchmark, with a 1-week return of 8.05% compared to the Sensex's 2.00% and a year-to-date return of 53.90% versus the Sensex's 7.58%. This strong relative performance highlights the stock's appeal in the current market environment. The rising investor participation, evidenced by a 57.74% increase in delivery volume, further supports the stock's upward movement. Overall, the combination of strong short-term gains, solid management efficiency, and positive market sentiment contributes to the stock's rising price.